Effects of SGLT2 Inhibitors on Proteinuria and Renal Function Parameters in Non-Diabetic Kidney Transplant Recipients: A Retrospective Cohort Study Based on 12-Month Follow-Up Data
Journal of Clinical Medicine · 07.07.2026 · 15 (13) · 5303
DOI: 10.3390/jcm15135303 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.07.2026. Verfasst von Serdar Kahvecioglu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Bursa Yüksek İhtisas Training and Research Hospital, 16260 Bursa, Türkiye. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated significant renoprotective effects in patients with chronic kidney disease. However, kidney transplant recipients have been excluded from major randomized trials, and evidence in non-diabetic transplant patients remains limited. This study aimed to investigate the potential effects of SGLT2 inhibitors in non-diabetic kidney transplant recipients.
Methods
Kidney transplant recipients were screened retrospectively and divided into two groups based on SGLT2 inhibitor use. A total of 18 non-diabetic patients receiving SGLT2 inhibitors (Group 1) were compared with 30 matched controls (Group 2). Patients were followed at baseline, 3, 6, and 12 months. Proteinuria, serum creatinine, eGFR, uric acid, and tacrolimus levels were analyzed.
Results
Baseline demographic and biochemical characteristics were similar between groups. In Group 1, proteinuria decreased by 20% at 6 months and 26% at 12 months compared with baseline. The reduction in proteinuria from baseline to 6 months was significantly greater in Group 1 than in controls (p = 0.037). No significant changes were observed in serum creatinine, eGFR, tacrolimus levels, or infection-related adverse events between groups.
Conclusions
SGLT2 inhibitors may confer an early antiproteinuric benefit in non-diabetic kidney transplant recipients without apparent adverse effects on renal function or safety. Larger prospective studies are needed to confirm long-term effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Bursa Yüksek İhtisas Training and Research Hospital, 16260 Bursa, Türkiye.
- Department of Nephrology, Bursa Acıbadem Hospital, 16210 Bursa, Türkiye.
- Department of Internal Medicine, Bursa Yüksek İhtisas Training and Research Hospital, 16260 Bursa, Türkiye.
ORCID-Profile: Asena Serap Karatutlu, Saide Elif Gullulu Boz, Ozger Akarsu, Nazife Nur Ozer Sensoy
Zitieren
APA
Kahvecioglu, S., Celik, H., Karatutlu, A. S., Gullulu Boz, S. E., Ozdemir, P., Akarsu, O., Ozer Sensoy, N. N., & Aktas, N. (2026). Effects of SGLT2 Inhibitors on Proteinuria and Renal Function Parameters in Non-Diabetic Kidney Transplant Recipients: A Retrospective Cohort Study Based on 12-Month Follow-Up Data. Journal of Clinical Medicine, 15(13), 5303. https://doi.org/10.3390/jcm15135303
Vancouver
Kahvecioglu S, Celik H, Karatutlu AS, Gullulu Boz SE, Ozdemir P, Akarsu O, et al. Effects of SGLT2 Inhibitors on Proteinuria and Renal Function Parameters in Non-Diabetic Kidney Transplant Recipients: A Retrospective Cohort Study Based on 12-Month Follow-Up Data. Journal of Clinical Medicine. 2026;15(13):5303. doi:10.3390/jcm15135303
BibTeX
@article{Kahvecioglu2026,
author = {Kahvecioglu, Serdar and Celik, Huseyin and Karatutlu, Asena Serap and Gullulu Boz, Saide Elif and Ozdemir, Pinar and Akarsu, Ozger and Ozer Sensoy, Nazife Nur and Aktas, Nimet},
title = {Effects of SGLT2 Inhibitors on Proteinuria and Renal Function Parameters in Non-Diabetic Kidney Transplant Recipients: A Retrospective Cohort Study Based on 12-Month Follow-Up Data},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {5303},
doi = {10.3390/jcm15135303}
}
EUVIMED